ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

ANVS Annovis Bio Inc

5.56
-1.72 (-23.63%)
30 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Annovis Bio Inc ANVS NYSE Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-1.72 -23.63% 5.56 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
6.89 5.3677 6.89 5.57 7.28
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
29/4/202409:10GLOBEAnnovis Bio Announces Statistically Significant Phase II/III..
02/4/202406:30GLOBEAnnovis Bio Provides Corporate Updates and Reports Fourth..
28/2/202406:08IHMARKETNEWSUS Stock Movers Before Market: Beyond Meat, eBay, First..
12/2/202413:00EDGAR2Form S-3/A - Registration statement under Securities Act of..
01/2/202415:05EDGAR2Form S-3 - Registration statement under Securities Act of..
22/11/202315:27EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
21/11/202313:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202313:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202313:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202313:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202315:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202306:30BWAnnovis Bio Measures Novel Biomarkers in Plasma of..
01/11/202311:28EDGAR2Form 8-K - Current report
01/11/202311:24EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/10/202307:00BWAnnovis Bio Announces Pricing of $7.5 Million Public..
30/10/202316:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/10/202316:17EDGAR2Form 8-K - Current report
30/10/202315:48BWAnnovis Bio Announces Launch of Proposed Public Offering
30/10/202315:42BWAnnovis Bio Receives Positive Recommendation to Continue..
24/10/202308:13BWAnnovis Bio Showcases Promising Progress in Novel Drug..
21/9/202308:35GLOBEDawson James Securities Announces October Date for 8th..
15/8/202306:20BWAnnovis Bio Announces Second Quarter 2023 Financial Results..
14/8/202315:40EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
18/7/202307:18BWContinued Positive Performance of Novel Drug Development by..
27/6/202306:30BWAnnovis Bio Announces the Filing of a Groundbreaking Patent
20/6/202311:05BWAnnovis Bio Receives Excellent Safety Rating and Positive..
08/6/202306:30PRNUSAnnovis Bio Announces Completion of Phase III Parkinson's..

Su Consulta Reciente

Delayed Upgrade Clock